Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

BACKGROUND: Certolizumab pegol (CZP) is an Fc‐free, PEGylated anti‐tumour necrosis factor biologic. OBJECTIVES: To report 3‐year safety data from three phase III trials of CZP in adults with plaque psoriasis. METHODS: Data were pooled from CIMPASI‐1 (NCT02326298), CIMPASI‐2 (NCT02326272) and CIMPACT...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R.B., Gottlieb, A.B., Langley, R.G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., Reich, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246928/
https://www.ncbi.nlm.nih.gov/pubmed/32531798
http://dx.doi.org/10.1111/bjd.19314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246928/
https://www.ncbi.nlm.nih.gov/pubmed/32531798
http://dx.doi.org/10.1111/bjd.19314

Ejemplares similares